KZIA
Kazia Therapeutics Limited American Depositary Shares
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Kazia Therapeutics (KZIA) Stock: Buy, Sell, or Hold?
$6.62
-0.33 (-4.75%)
▼
5d:
-7.8%
30d:
-10.54%
90d:
-51.18%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (53%)
Quality Score
40/100
Position
OVERSOLD
30-Day Fair Range
$7.24 – $8.72
Position: OVERSOLD
Forward P/E & Valuation
-848.7x
Next 12M consensus est.
Wall Street Target
$28.49
+330.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$6.26 / $8.75
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: KZIA shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When KZIA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: KZIA is currently trading at $6.62, which is considered oversold relative to its 30-day fair value range of $7.24 to $8.72.
Technical Outlook: Technically, KZIA is in a strong downtrend. Immediate support is located at $6.25, while resistance sits at $8.75. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: KZIA scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.49 (+330.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KZIA is in a strong downtrend. Immediate support is located at $6.25, while resistance sits at $8.75. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: KZIA scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.49 (+330.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.24 -
$8.72
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Trading Range & Key Levels
30-Day Trading Range
$7.24 -
$8.72
Current vs Trading Range
OVERSOLD
Support Level
$6.26
Resistance Level
$8.75
Current Trend
Strong Downtrend
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 330.3% below Wall St target ($28.49)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-848.72
Wall Street Target
$28.49
(+330.3%)
Revenue Growth (YoY)
312.4%
Share KZIA Analysis
Share this live KZIA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 13, 2026 5:34 PM ET
Data refreshes hourly during market hours. Next update: 6:34 PM
Data refreshes hourly during market hours. Next update: 6:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KZIA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 33 SELL |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
18 analysts |
$139 | 35 SELL |
|
ARDX
Ardelyx Inc |
STRONG BUY
11 analysts |
$13 | 69 BUY |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive KZIA Research Pages
